EDNRA and pulmonary arterial hypertension: Although the inhibition of ET-A activity by ET-A-selective or non-selective agents causes hepatotoxicity during PAH treatment, it provides sustained functional and physiological improvements to the pulmonary artery and relief of PAH symptoms.93, 94 It has long been regarded that NO is an important factor in vascular homeostasis.